New Molecular Targets for the Treatment of Neovascular Age-Related Macular Degeneration

Translational Medicine Reports
doi 10.4081/tmr.6819
Full Text
Abstract

Available in full text

Date
Authors
Publisher

PAGEPress Publications

Related search

Treatment of Age-Related Neovascular Macular Degeneration: The Patient’s Perspective

Graefe's Archive for Clinical and Experimental Ophthalmology
Molecular NeuroscienceOphthalmologySensory SystemsCellular
2017English

Aflibercept for Neovascular Age-Related Macular Degeneration

Cochrane Database of Systematic Reviews
2016English

Patient Preferences in the Treatment of Neovascular Age-Related Macular Degeneration

Ophthalmology
Ophthalmology
2016English

Macular Atrophy in Neovascular Age Related Macular Degeneration

Journal of Clinical Review & Case Reports
2019English

Development and Testing of a Patient-Derived Questionnaire for Treatment of Neovascular Age-Related Macular Degeneration: Dimensions of Importance in Treatment of Neovascular Age-Related Macular Degeneration

Acta Ophthalmologica
MedicineOphthalmology
2018English

Ranibizumab Versus Verteporfin for Neovascular Age-Related Macular Degeneration

New England Journal of Medicine
Medicine
2006English

Pss62 - Treatment Preference Drivers of Patients With Neovascular Age-Related Macular Degeneration

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Profile of Conbercept in the Treatment Of neovascular Age-Related Macular Degeneration

Drug Design, Development and Therapy
Drug DiscoveryPharmacologyPharmaceutical Science
2015English

Brolucizumab: Evidence to Date in the Treatment of Neovascular Age-Related Macular Degeneration

Clinical Ophthalmology
Ophthalmology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy